Mirtazapin Hormosan (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hormosan, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirtazapin Hormosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on central neurotransmitter pathways to alleviate depressive conditions. - Major depressive disorder: reduces depressive symptoms in adult patients. - Depressive episodes associated with bipolar disorder: helps alleviate the depressive phase. - Treatment‑resistant depression (adjunct therapy): may be added when first‑line agents are insufficient.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension or syncope - Hepatic injury or jaundice - Seizures (rare)

Before prescribing Mirtazapine, clinicians should consider several safety aspects. - Hepatic function: assess liver status in patients with known impairment. - Suicidal ideation: monitor closely during the initial treatment period. - Cardiovascular disease: use caution in patients with existing hypotension or arrhythmias. - Discontinuation: avoid abrupt cessation to reduce risk of withdrawal symptoms. - Elderly patients: start at low dose due to increased sensitivity to sedation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may require dose adjustment. - Anticholinergic drugs: increased anticholinergic burden may worsen dry mouth and constipation.